Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

Slides:

Advertisements

Similar presentations

Teaching NeuroImages Neurology Resident and Fellow Section © 2013 American Academy of Neurology An unusual cause of conus medullaris syndrome.

Advertisements

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Advances in Translational Research in Neuro-oncology.

Genome evolution within the individual

Sarah Leary, MD MS CBTTC 5/25/2016

Figure 1 Sequence chromatograms of DNA isolated from two patients with sporadic KIT/PDGFRA wild-type gastrointestinal stromal tumors. A ) Region harboring.

Enhanced DNA damage in IDH1 mutant glioma cells.

IDH1 mutant glioma cells are sensitive to TMZ

Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

A, baseline and 4-week PET scan from patient 2 (MET c

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Intrinsic and acquired trastuzumab resistance.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Figure 1 Mutations in SPG7 in a family with primary lateral sclerosis

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

A, In a patient with a history of breast cancer surgery and radiation treatment with right-arm weakness, axial T2WI shows diffuse thickening of the right.

Fig. 2 Estimate of the neoantigen repertoire in human cancer.

BRCA1 promoter methylation detected in the peripheral blood and corresponding tumor. BRCA1 promoter methylation detected in the peripheral blood and corresponding.

Integrated mRNA and microRNA expression and DNA methylation clusters.

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

Immunohistochemical detection of nuclear and cytoplasmic YB-1 in osteosarcoma and synovial sarcoma. Immunohistochemical detection of nuclear and cytoplasmic.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

A, Proportion of variants detected in the MMR genes.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

GM-CSF is required for CA-MSC–induced tumor metastasis.

Number of identical D-loop DNA clones detected in 10 DNA clones derived from liver tumor tissues. Number of identical D-loop DNA clones detected in 10.

HGSOC mutational processes are established early and are patient-specific. HGSOC mutational processes are established early and are patient-specific. A,

Extraction diagram of candidate genes identified by global expression analysis. Extraction diagram of candidate genes identified by global expression analysis.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Location of the ER mutations and frequencies per cohort.

Frequent coamplification of RTKs in MET-amplified EGC

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Representative patient responses to ulixertinib.

Western blotting confirming the presence of fusion proteins in tumor lysates and showing increased signaling pathway activation in respective tumors. Western.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

Strategies for personalized precision immunotherapy.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Defining the eTME genes.

JAK3 mutations and ectopic expression of HOXA9 are significantly associated in clinical T-ALL cases. JAK3 mutations and ectopic expression of HOXA9 are.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Core melanoma escape pathways during disease progression on BRAF inhibitor therapy. Core melanoma escape pathways during disease progression on BRAF inhibitor.

A–D, FGFR3 gatekeeper mutations detected in 4 patients.

The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Genomic instability is a core feature of ovarian cancer that frequently involves DNA-damage repair genes. Genomic instability is a core feature of ovarian.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Molecular characterization of esophagogastric tumors.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

MRI Atlas of IDH-Wildtype Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes A 3D atlas of glioblastoma location was.

Presentation transcript:

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in an adult patient. A, a left frontoinsular enhancing tumor was identified at presentation and resected. Following concomitant temozolomide and radiation treatment, an intradural/extramedullary C7-T2 metastasis was identified and also resected. Following a course of pembrolizumab, a second intradural/extramedullary metastasis at T7-8 was resected. All tumors were glioblastoma with PNET features. B, mutational burden as detected by whole-exome DNA sequencing. Each tumor harbored between 9,000 and 11,000 nonsynonymous mutations. C, all tumors carried a nearly identical spectrum of mutations, with the majority C>G alterations. D, relative expression of MGMT by RNA sequencing across each tumor. Tanner M. Johanns et al. Cancer Discov 2016;6:1230-1236 ©2016 by American Association for Cancer Research